Categories
- Clinical Practice (2)
- Current Research (22)
- Diabetes in the Press (5)
- Diabetes Technology (2)
- Diatribe (1)
- Guest Essays (2)
- Islet Sheet Updates (7)
- Press Release (1)
- Scott's Opinion (21)
- The Marat/King Dialogues (8)
- Type 1 Diabetes Classic (5)
- Uncategorized (3)
Blog Archives
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
Archive for October, 2010
Animal "Models" of Autoimmune Diabetes
October 24th, 2010
A friend who worked at the FDA had a Harris cartoon of two medical researchers, one saying to the other, “This drug will bestow immortality. Unfortunately it will take forever to prove it.” In medical research we are expected to prove our claims. We believe the Islet Sheet will be a functional cure of autoimmune [...]
Irvine scientist works on transplant to help diabetes patients
October 14th, 2010
Dr. Jonathan Lakey has been interviewed about the Solving Diabetes Research on KPCC / Southern California Public Radio.
Progress in Rat Studies: Learning to Make a Rat Really Diabetic
October 10th, 2010
What is worse than seeking something with a flashlight that does not work? I would say seeking something with a flashlight that may not be working!
If you are reading this it is likely that you are interested in the promise and prospects for the Islet Sheet. Naturally there is great interest in our studies of Islet Sheets in diabetic rats. A couple of months ago I published partial results from an ongoing experiment. Here is the promised update.
The 30th Anniversary of "Prospects in Diabetes Therapy"
October 3rd, 2010
Thirty Years ago a Wall Street Investment Banking firm published a research report on the future of the diabetes industry. It was the first time a Wall Street firm had ever considered diabetes as an investment opportunity. The author was a 25-year old who had had type 1 diabetes for two years. That was me.
